Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary sjögren's syndrome: A randomised, double-blind, placebo-controlled, phase 2b dose-finding trial - Bowman, S J; Fox, R; Dörner, T (Lancet., 2022)